Search
Velmanase alfa
go.drugbank.com/drugs/DB12374ApprovedInvestigationalPatients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex sugars in the body. … Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder.
Seladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigationalSeladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration. … [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism
Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15740InvestigationalCurrently, OM-MSCs does not have wide application as there is not yet a standard and unambiguous protocol for OM-MSC collection, isolation, and therapeutic application. … Human olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) reside in an accessible location of the nasal cavity and have properties of multipotency and high proliferation, which contributes to high
Synonyms: OM-MSCTacrine
go.drugbank.com/drugs/DB00382ApprovedWithdrawnA centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous
Phendimetrazine
go.drugbank.com/drugs/DB01579ApprovedIllicitPhendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.
Levobupivacaine
go.drugbank.com/drugs/DB01002ApprovedInvestigationalWithdrawnIn particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. … When administered appropriately, the occurrence of adverse effects is not anticipated much if at all.
Denufosol
go.drugbank.com/drugs/DB04983InvestigationalDenufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.
Certolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigational[A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. … done directly in bacterial hosts such as _E. coli_.
Polatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigationalPolatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. … [L6658] The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigationalIt was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. … Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors.